Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Phytocannabinoids, primarily cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) derived from the cannabis plant, have been investigated for their potential to support or treat insomnia. Scientific interest in cannabinoids for sleep disorders has grown, with several clinical studies and systematic reviews conducted over the past decade. Evidence suggests that cannabinoids may modulate the endocannabinoid system, which plays a role in regulating sleep-wake cycles. Some studies indicate that THC can reduce sleep latency (the time it takes to fall asleep) and increase total sleep duration, while CBD has been associated with both wake-promoting and sedative effects, depending on the dose and timing of administration.

A 2019 review in Current Psychiatry Reports concluded that there is moderate evidence for cannabinoids improving sleep in certain populations, particularly those with chronic pain or other comorbidities. However, the quality of available studies varies, and many have small sample sizes, short durations, or lack placebo controls. Side effects, potential for dependence (especially with THC), and long-term safety are also concerns. The American Academy of Sleep Medicine currently does not recommend cannabinoids for routine insomnia management due to insufficient high-quality evidence. While some individuals report subjective improvement in sleep, more rigorous research is needed to define optimal dosing, formulation, and long-term efficacy.

In summary, while there is some scientific validation for the use of phytocannabinoids in treating insomnia, particularly in specific populations, the overall evidence is moderate and not yet sufficient for broad clinical recommendations.

More about phytocannabinoids
More about Insomnia

Other ingredients used for Insomnia

Other health conditions supported by phytocannabinoids

Products containing phytocannabinoids